We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Multiple states accused RB Group and its former subsidiary Indivior of falsely promoting Suboxone as less susceptible to diversion and abuse. Read More
In an Oct. 28-31 meeting, the EMA’s pharmacovigilance risk assessment committee (PRAC) warned against the use of Sanofi’s multiple sclerosis drug Lemtrada (alemtuzumab) in patients with certain heart, circulation, bleeding or auto-immune disorders besides multiple sclerosis. Read More
The generic manufacturers are accused of “routinely and systematically” communicating with each other to determine their market share and customers. Read More
A new draft guidance from the FDA encourages drugmakers to speed up development of Hepatitis D treatments for use in the U.S., offering recommendations for innovative trial designs, target populations and endpoints. Read More
Acting FDA Commissioner Ned Sharpless ends his six-month stint at the agency today, and the White House is expected to nominate oncologist Stephen Hahn to fill the permanent role. Read More